Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects
- 18 November 2016
- journal article
- research article
- Published by Informa UK Limited in Expert Opinion on Investigational Drugs
- Vol. 25 (12), 1361-1370
- https://doi.org/10.1080/13543784.2016.1255724
Abstract
This Phase I study (VOLTAIRE®-PK) aimed to evaluate three-way pharmacokinetic similarity (bioequivalence), safety, and immunogenicity of BI 695501 (a Humira® [adalimumab] biosimilar candidate) compared with US- and EU-approved Humira in healthy male subjects. Subjects (N = 327) were randomized 1:1:1 to receive one 40-mg subcutaneous dose of BI 695501, US- or EU-approved Humira; safety was assessed for 70 days. Bioequivalence was evaluated using the average bioequivalence method to test if the 90% confidence intervals (CIs) of the geometric means (BI 695501 vs US- and EU-approved Humira) for the primary end points were within prespecified acceptance ranges (80-125%). Immunogenicity was assessed using a sensitive bridging method. Bioequivalence between BI 695501 and US- and EU-approved Humira was demonstrated with the 90% CIs of the ratios of all primary end points: Cmax, AUC0-inf, pred and AUC0-tz being within the prespecified acceptance ranges of 80-125%. Concentration vs time profiles were similar as were the time course and frequency of immunogenic responses. All study drugs showed similar safety and tolerability results. Three-way bioequivalence of BI 695501 to US- and EU-approved Humira was demonstrated; safety and immunogenicity results of the three study drugs were also similar. 2013-003722-84 (EudraCT) and NCT02045979.Keywords
Funding Information
- Boehringer Ingelheim (not applicable)
This publication has 16 references indexed in Scilit:
- Using the Anti-TNF Agents in PsoriasisSeminars in Cutaneous Medicine and Surgery, 2015
- Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical RecommendationsThe AAPS Journal, 2014
- Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximabAnnals Of The Rheumatic Diseases, 2013
- Inmunogenicidad en terapia biológica. Implicaciones en DermatologíaActas Dermo-Sifiliograficas, 2013
- The State of the Art in the Development of BiosimilarsCancer Cell, 2012
- Socioeconomic Burden of Immune-Mediated Inflammatory Diseases -- Focusing on Work Productivity and DisabilityThe Journal of Rheumatology Supplement, 2011
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's DiseaseGastroenterology, 2009
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort studyAnnals Of The Rheumatic Diseases, 2009
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2007
- Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolutionPostgraduate Medical Journal, 2007